Sorrento Therapeutics Inc (SRNE) : Aisling Capital has sold out all of its stake in Sorrento Therapeutics Inc during the most recent quarter, according to the disclosure filed by the company on May 13, 2016 with the SEC. The investment management company has sold out 3,855 shares of Sorrento Therapeutics Inc which is valued at $22,051.
Other Hedge Funds, Including , Citadel Advisors sold out all of its stake in SRNE during the most recent quarter. The investment firm sold 28,792 shares of SRNE which is valued $164,690. Landscape Capital Management L.l.c. sold out all of its stake in SRNE during the most recent quarter. The investment firm sold 54,634 shares of SRNE which is valued $312,506.Mutual Of America Capital Management reduced its stake in SRNE by selling 1,100 shares or 0.72% in the most recent quarter. The Hedge Fund company now holds 152,018 shares of SRNE which is valued at $869,543. Sorrento Therapeutics Inc makes up approx 0.02% of Mutual Of America Capital Management’s portfolio. Financial Architects Inc added SRNE to its portfolio by purchasing 2,500 company shares during the most recent quarter which is valued at $14,300. Sorrento Therapeutics Inc makes up approx 0.01% of Financial Architects Inc’s portfolio.
Sorrento Therapeutics Inc opened for trading at $6.54 and hit $6.7 on the upside on Wednesday, eventually ending the session at $6.62, with a gain of 1.53% or 0.1 points. The heightened volatility saw the trading volume jump to 2,01,852 shares. Company has a market cap of $266 M.
Many Wall Street Analysts have commented on Sorrento Therapeutics Inc. Shares were Reiterated by FBR Capital on Apr 6, 2016 to “Outperform” and Lowered the Price Target to $ 16 from a previous price target of $21 .Shares were Reiterated by FBR Capital on Mar 16, 2016 to “Outperform” and Lowered the Price Target to $ 21 from a previous price target of $22 .
Sorrento Therapeutics Inc. is a biopharmaceutical company. The Company is engaged in the discovery acquisition development and commercialization of drug therapeutics for addressing unmet medical needs in the United States Europe as well as international markets. Its primary therapeutic focus is oncology including the treatment of chronic cancer pain but it is also developing therapeutic products for other indications including immunology and infectious diseases. Its products in the pipeline include Cynviloq and resiniferatoxin (RTX) a non-opiate ultra-potent and selective agonist of the transient receptor potential cation channel subfamily V member 1 (TRPV-1) receptor. Its pipeline also includes preclinical human therapeutic monoclonal antibodies (mAbs) antibody drug conjugates (ADCs) bispecific antibodies (BsAbs) as well as Chimeric Antigen Receptor Tumor-attacking Neukoplast (CAR.TNK) for adoptive cellular immunotherapies (ACI).